---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-036247"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2024-11-26T23:59:59+00:00"
generated_at: "2026-05-29T17:32:50.072685+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dyadic receives $3.1M Gates Foundation grant for RSV and malaria mAb development

## Summary
- Grant of $3,092,136 from Bill & Melinda Gates Foundation for monoclonal antibody development using C1 platform.
- Targets RSV (100K+ deaths annually, 99% in LMICs) and malaria (249M cases, 608K deaths in 2022).
- Aims to reduce production costs and improve global access to affordable therapeutics for underserved populations.
- Dyadic plans to commercialize resulting antibodies via licensure if development succeeds.

## SEC filing metadata
- accession: 0001437749-24-036247
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2024-11-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774924036247/0001437749-24-036247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774924036247/dyai20241120_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-036247
- JSON: https://secwatch.observer/filing/0001437749-24-036247.json
- Plain text: https://secwatch.observer/filing/0001437749-24-036247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.